Eloralintide Peptide: Sequence, Mechanism and Research Considerations

Eloralintide, also known as LY3841136, is an investigational, long-acting amylin receptor agonist developed by Eli Lilly and Company. For peptide researchers, its interest extends beyond the clinical development program: the molecule combines a modified amylin backbone, a stabilized sulfur-containing bridge and a site-specific lipid side chain.

Understanding those features is essential when interpreting a sequence listing, comparing receptor data or reviewing analytical documentation. A peptide name and an amino-acid string alone do not fully specify the molecule.

What Is Eloralintide?

Eloralintide belongs to the amylin-analog class. Its pharmacology is distinct from GLP-1 receptor agonism, although both pathways are being investigated in metabolic disease.

As of September 12, 2026, Lilly lists eloralintide in Phase 3 development for obesity. This development status describes an investigational medicine and does not establish the identity, quality or clinical suitability of independently supplied research material. [1]

The published 48-week Phase 2 study enrolled 263 adults with obesity, or overweight with a weight-related comorbidity, without type 2 diabetes. That study provides clinical context for interest in the molecule, but its findings should remain separate from specifications for a laboratory peptide or claims about an independently prepared sample. [2]

Eloralintide Sequence and Structural Features

The publicly disclosed structure contains a 37-residue main chain and a C-terminal amide. Its annotated sequence can be represented as follows:

Residues 1–10:
γGlu–Cys–Asn–Thr–Ala–Thr–Cys–Ala–Thr–Gly

Residues 11–20:
Orn–Leu–Ala–Glu–αMePhe–Leu–Val–Arg–Ser–Ser

Residues 21–30:
Asn–NMeAsn–Phe–Gly–Pro–Lys*–Leu–Pro–Pro–Thr

Residues 31–37:
Glu–Val–Gly–Ser–Asn–Thr–Tyr–NH₂

Here, γGlu denotes gamma-L-glutamic acid, Orn denotes L-ornithine, αMePhe denotes alpha-methyl-L-phenylalanine, and NMeAsn denotes N-methyl-L-asparagine. Lys* at position 26 carries a side chain comprising two gamma-glutamate units and a C20 fatty diacid. Cys2 and Cys7 are connected through an S–CH₂–S methylene thioacetal bridge. [3,4]

We recommend using the annotated sequence together with the published structural drawing when specifying research material. Simplifying the sequence for database entry should not erase the information needed to distinguish the intended molecule from an analog.

How to Interpret Its Amylin Receptor Activity

Figure 1: Eloralintide potency at human AMY1, AMY3 and calcitonin receptors measured in a cAMP assay using receptor-expressing UMUC3 cells under albumin-free conditions. Reported EC50 values were 23.9 ± 1.1, 253.8 ± 9.7 and 291.0 ± 27.0 pM, respectively (mean ± SE). Lower EC50 indicates greater potency within this assay; these results do not directly establish clinical efficacy. Replotted from Briere et al., Molecular Metabolism (2025).

Amylin receptors contain the calcitonin receptor together with a receptor activity-modifying protein. AMY1 comprises the calcitonin receptor and RAMP1; the receptor composition therefore matters when interpreting an assay described simply as an “amylin receptor” experiment. [5]

In the discovery study, eloralintide produced cAMP responses with EC50 values of 23.9 pM at human AMY1R, 253.8 pM at human AMY3R and 291.0 pM at human calcitonin receptor. These measurements used receptor-expressing UMUC3 cells under albumin-free conditions. They support preferential AMY1R potency in that system, not an absence of activity at the other receptors. [3]

For comparative research, record the receptor subtype, species, cell system and functional readout alongside the concentration–response result. A binding measurement and a cAMP response address different aspects of pharmacology and should not be treated as interchangeable.

Why Albumin Conditions Matter

The discovery report associates eloralintide’s lipid side chain with albumin binding and prolonged exposure. It also reports reduced apparent potency of lipidated peptides when the functional assays included 1% human serum albumin. [3]

This creates a practical interpretation issue. Two experiments can use the same nominal peptide concentration while exposing receptors to different available fractions. A change in measured potency may therefore reflect assay composition as well as receptor interaction.

We recommend treating albumin concentration as part of the assay definition when comparing lipidated amylin analogs. A useful comparison documents protein supplementation and sample preparation, then evaluates candidates under matched conditions. The published albumin-free values should not be adopted as universal acceptance limits for a different assay.

The broader relationship between lipidation and exposure is discussed in Peptide Lipidation: Half-Life, Albumin Binding and Design.

Synthesis Considerations Follow From the Complete Structure

A synthesis assessment should begin with the annotated molecular specification. Backbone assembly is only one component; the bridge, terminal chemistry and site-specific side chain must also be accounted for.

The following considerations are structural planning judgments, rather than a description of Lilly’s manufacturing process. The protected building blocks and coupling strategy need to accommodate the noncanonical residues. Modification planning must distinguish the intended lysine attachment site from other available amino groups. Bridge formation must deliver the specified sulfur connectivity.

We consider bridge identity a particularly important review point. An oxidation step designed to produce a conventional disulfide would not, by itself, produce the specified methylene thioacetal. A proposal that refers only to “Cys2–Cys7 cyclization” leaves a chemically important ambiguity unresolved.

A useful project assessment should therefore identify how each defining feature will be installed and verified. It should not infer feasibility, yield or reproducibility from the residue count alone.

Purification and QC Should Answer Separate Questions

Purity, identity and peptide content are related but distinct measurements. Chromatography describes the components resolved under the selected conditions. Mass spectrometry provides molecular-mass information and can help characterize impurities. Quantitative analysis establishes the amount of peptide used to assign concentration. General peptide-quality guidance supports retaining these different forms of evidence rather than relying on a single percentage. [6]

For a structurally modified peptide, a matching intact mass does not establish every attachment position or stereochemical feature. The analytical plan should address the specific ambiguities left by the synthesis route, using additional characterization where necessary.

When reviewing a batch, ask whether the analytical record supports the complete specified molecule. The chromatogram, mass data, concentration basis and any modification-specific evidence should refer to the same batch. Unresolved peaks or discrepancies need an explanation before biological differences are attributed to receptor pharmacology.

For method-development context, see Peptide Purification by RP-HPLC: Method Development and Scale-Up.

Research Use Starts With a Defined Comparison

Eloralintide-related research can examine receptor-subtype responses, the effect of assay protein conditions, or relationships between a specified structural modification and measured behavior. Each study needs a clearly identified test article and a comparison appropriate to its question.

A modified analog, labeled derivative or peptide lacking the lipid side chain should be identified as such. Findings from that material cannot automatically be assigned to the fully modified molecule. Similarly, a literature reference establishes what the authors studied; it does not authenticate another sample carrying the same name.

For research planning, the most useful starting information is the annotated structure, the intended assay and the evidence needed to interpret its result. This connects molecular identity to experimental meaning and makes subsequent synthesis and analytical discussions more precise.

Frequently Asked Questions About Eloralintide

Is eloralintide a GLP-1 receptor agonist?

Eloralintide (LY3841136) is a long-acting amylin receptor agonist, not a GLP-1 receptor agonist. Although both pathways are studied in weight management, they involve different receptor systems. When comparing eloralintide with other investigational peptides, distinguish receptor pharmacology from outcomes measured in separate clinical studies. [1]

Is the amino acid sequence enough to identify eloralintide?

A conventional amino acid sequence alone does not fully describe eloralintide. Its identity also depends on modified residues, the methylene thioacetal bridge connecting Cys2 and Cys7, the lipid-containing side chain attached at Lys26, and C-terminal amidation. For research material assessment, check the complete annotated structure and supporting analytical evidence rather than relying only on a sequence string or product name. [1]

Why do albumin conditions matter when comparing eloralintide potency?

Albumin can change the apparent potency of lipidated peptides by affecting the fraction available to interact with receptors. In the published eloralintide study, adding 1% human serum albumin reduced its apparent potency in cellular receptor assays compared with albumin-free conditions. Compare EC50 values alongside the receptor subtype, cell system and albumin conditions; values obtained under different conditions are not directly interchangeable. [1]

References

1. Eli Lilly and Company. Clinical Development Pipeline. Accessed September 12, 2026. Lilly pipeline.

2. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 2025;406(10520):2631–2643. doi:10.1016/S0140-6736(25)02155-5.

3. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular Metabolism. 2025;102:102271. Full article.

4. Eli Lilly and Company. Introduction to Eloralintide. ObesityWeek 2025 symposium presentation, slide 2. Structural sequence and notation.

5. IUPHAR/BPS Guide to PHARMACOLOGY. AMY1 receptor. Receptor entry.

6. Hoofnagle AN, et al. Recommendations for the generation, quantification, storage and handling of peptides used for mass spectrometry-based assays. Clinical Chemistry. 2016;62(1):48–69. Full article.

This article discusses research literature and laboratory considerations. It does not provide instructions for human use.